The latest news:

• Help us better Understand Patient Experiences with Glioblastoma Multiforme         This is a survey from a market research group.  If you participate in a phone call, they will send you $125, and the Musella Foundation also gets a donation!    This is only for GBM patients or people who care for a gbm patient.   Let me know if you participate!
  



• DelMar Pharmaceuticals Inc (DMPI) Moves Forward With Flagship Chemotherapy Into Phase II         This is an open label trial - which means we should be able to find out how good it works quickly. Hopefully by the end of this year.
  



• VBI Vaccines Building On Duke University Research for New Cancer Therapy        Exciting.  Early trials of the vaccine looked good.
  



• TRACON Pharmaceuticals Announces Top-line Results from NCI-Sponsored Phase 2 Trial of TRC105 in Recurrent Glioblastoma         Unfortunately, the trial failed.
  



• Trials Open for Enrollment: Phase II Study of VAL-083 in Patients with MGMT-unmethylated Bevacizumab-naïve Recurrent Glioblastoma Multiforme         I have talked about Val-083 a lot over the last year. The trial is finally open.  This is a great option for recurrent GBM patients with unmethylated MGMT.
  

BrainTumor Co-Payment Assistance Program Status:

• CLOSED to new applicants